2016
DOI: 10.1172/jci81129
|View full text |Cite
|
Sign up to set email alerts
|

Extracellular vesicle isolation and characterization: toward clinical application

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

12
619
0
6

Year Published

2016
2016
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 726 publications
(637 citation statements)
references
References 147 publications
12
619
0
6
Order By: Relevance
“…To confirm that the purified exosomes also met the standards in this field, we analyzed the features of exosomes by transmission electron microcopy. As shown in Figure 1D, the exosomes presented as cup-shaped membrane vesicles of 50 to 90 nm, as previously reported (32,33). Approximately 42% of TPO, 42% of ANGPTL2, and 62% of ANGPTL3 were located in exosomes marked by TSG101 and flotillin 1 (FLOT1) ( Figure 1E), and purified exosomes from human plasma contained a large amount of TPO, ANGPTL2, and ANGPTL3 proteins ( Figure 1F).…”
Section: Introductionsupporting
confidence: 81%
“…To confirm that the purified exosomes also met the standards in this field, we analyzed the features of exosomes by transmission electron microcopy. As shown in Figure 1D, the exosomes presented as cup-shaped membrane vesicles of 50 to 90 nm, as previously reported (32,33). Approximately 42% of TPO, 42% of ANGPTL2, and 62% of ANGPTL3 were located in exosomes marked by TSG101 and flotillin 1 (FLOT1) ( Figure 1E), and purified exosomes from human plasma contained a large amount of TPO, ANGPTL2, and ANGPTL3 proteins ( Figure 1F).…”
Section: Introductionsupporting
confidence: 81%
“…Importantly, this data cannot distinguish whether increased alternative pathway activation is a cause of disease or simply a marker of inflammation in CKD. Another potential limitation is the absence of standardized methodology for the measurement of microparticles in humans 51. Notwithstanding these limitations, data such as ours may lead to greater interest in microparticles, and future studies should focus on evaluating the methodology and whether in fact microparticles may be a valid marker of CVD.…”
Section: Discussionmentioning
confidence: 94%
“…For example, development of a pre-amplification of EV mRNA or a more sensitive quantification method. In addition, although there will be some difficulties and cautionary notes, [18][19][20] in order to not only make Ct-OATP1B3 mRNA detection more easily, but also to specify its origin, consideration should be given to collect and concentrate CRC-specific EVs from whole serum in future studies.…”
Section: Discussionmentioning
confidence: 99%